Last reviewed · How we verify
injection of placebo of apomorphine
injection of placebo of apomorphine is a Dopamine agonist Small molecule drug developed by University Hospital, Toulouse. It is currently in Phase 3 development for Parkinson's disease, Drug-induced extrapyramidal reactions.
Apomorphine is a dopamine agonist that mimics the action of dopamine in the brain.
Apomorphine is a dopamine agonist that mimics the action of dopamine in the brain. Used for Parkinson's disease, Drug-induced extrapyramidal reactions.
At a glance
| Generic name | injection of placebo of apomorphine |
|---|---|
| Sponsor | University Hospital, Toulouse |
| Drug class | Dopamine agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Apomorphine works by binding to dopamine receptors in the brain, which can help to alleviate symptoms of Parkinson's disease. This is achieved by mimicking the action of dopamine, a neurotransmitter that is often deficient in individuals with Parkinson's disease. By increasing dopamine activity, apomorphine can help to improve motor function and reduce symptoms such as tremors and rigidity.
Approved indications
- Parkinson's disease
- Drug-induced extrapyramidal reactions
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Orthostatic hypotension
Key clinical trials
- Clinical Trial of Intranasal Delivery of NT-301 (PHASE1)
- Blinking and Yawning in Epilepsy: The Role of Dopamine (NA)
- Apomorphine Effects on Pain in Parkinson's Disease (PHASE2, PHASE3)
- Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500 (PHASE3)
- Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease (PHASE3)
- Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months (PHASE2, PHASE3)
- Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease (PHASE3)
- A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- injection of placebo of apomorphine CI brief — competitive landscape report
- injection of placebo of apomorphine updates RSS · CI watch RSS
- University Hospital, Toulouse portfolio CI
Frequently asked questions about injection of placebo of apomorphine
What is injection of placebo of apomorphine?
How does injection of placebo of apomorphine work?
What is injection of placebo of apomorphine used for?
Who makes injection of placebo of apomorphine?
What drug class is injection of placebo of apomorphine in?
What development phase is injection of placebo of apomorphine in?
What are the side effects of injection of placebo of apomorphine?
What does injection of placebo of apomorphine target?
Related
- Drug class: All Dopamine agonist drugs
- Target: All drugs targeting Dopamine receptor
- Manufacturer: University Hospital, Toulouse — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease
- Indication: Drugs for Drug-induced extrapyramidal reactions
- Compare: injection of placebo of apomorphine vs similar drugs
- Pricing: injection of placebo of apomorphine cost, discount & access